Brokerages Set The Beauty Health Company (NASDAQ:SKIN) Target Price at $2.46

The Beauty Health Company (NASDAQ:SKIN) has been given an average recommendation of “Reduce” by the eleven research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $2.46.

SKIN has been the subject of several analyst reports. Stifel Nicolaus decreased their price objective on Beauty Health from $4.00 to $2.00 and set a “hold” rating for the company in a report on Friday, July 26th. Piper Sandler reissued an “underweight” rating and set a $1.00 price target (down from $1.50) on shares of Beauty Health in a report on Friday, August 9th. Finally, Canaccord Genuity Group decreased their price objective on shares of Beauty Health from $2.00 to $1.25 and set a “hold” rating for the company in a research report on Monday, August 12th.

Insider Activity

In related news, Chairman Brent L. Saunders purchased 40,450 shares of Beauty Health stock in a transaction that occurred on Monday, August 12th. The stock was purchased at an average price of $1.08 per share, for a total transaction of $43,686.00. Following the transaction, the chairman now directly owns 5,921,769 shares in the company, valued at approximately $6,395,510.52. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 41.00% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. HighMark Wealth Management LLC acquired a new stake in Beauty Health in the 1st quarter valued at about $31,000. SageView Advisory Group LLC acquired a new stake in shares of Beauty Health in the 1st quarter worth $60,000. Caprock Group LLC purchased a new position in shares of Beauty Health during the 2nd quarter worth $38,000. Sanctuary Advisors LLC purchased a new position in shares of Beauty Health during the 2nd quarter worth $47,000. Finally, SG Americas Securities LLC acquired a new position in shares of Beauty Health during the 3rd quarter valued at about $37,000. 93.26% of the stock is owned by institutional investors and hedge funds.

Beauty Health Trading Up 3.8 %

Beauty Health stock opened at $1.63 on Friday. Beauty Health has a 52 week low of $0.91 and a 52 week high of $5.33. The stock has a 50-day moving average price of $1.51 and a 200 day moving average price of $2.16. The company has a quick ratio of 5.47, a current ratio of 6.49 and a debt-to-equity ratio of 7.96. The company has a market capitalization of $201.52 million, a price-to-earnings ratio of -2.33 and a beta of 0.94.

Beauty Health (NASDAQ:SKIN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The business had revenue of $90.60 million during the quarter, compared to analyst estimates of $98.46 million. Beauty Health had a negative return on equity of 4.57% and a negative net margin of 22.86%. Sell-side analysts anticipate that Beauty Health will post -0.2 EPS for the current year.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.